Last reviewed · How we verify
The R group
The R group, marketed by Beijing Tiantan Hospital, holds a position in the pharmaceutical market with its key composition patent expiring in 2028. The drug's primary strength lies in its current market presence, leveraging the protection of its key patent. The primary risk is the potential increase in competition post-2028, as the key patent expires and generic versions may enter the market.
At a glance
| Generic name | The R group |
|---|---|
| Sponsor | Beijing Tiantan Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010) (PHASE3)
- Improving Family Communication in Older Adults: A Pilot Randomized Controlled Trial (NA)
- The Impact of Breathing Training on PPSUI: A Randomized Controlled Trial (NA)
- First-in-Human PfSPZ-LARC2 Vaccination/CHMI (PHASE1)
- Tocilizumab in Lung Transplantation (PHASE2)
- Increasing the Coverage of Severe Acute Malnutrition (SAM) Treatment in Ethiopia (NA)
- A Study in Healthy Men to Find Out How Different Doses of BI 3009947 Are Tolerated and How Different Formulations or Food Influence How BI 3009947 is Taken up Into the Blood (PHASE1)
- Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- The R group CI brief — competitive landscape report
- The R group updates RSS · CI watch RSS
- Beijing Tiantan Hospital portfolio CI